Adding elotuzumab to myeloma treatment decreases risk of disease progression
the ONA take:
The addition of elotuzumab to lenalidomide and dexamethasone significantly reduced risk of disease progression or death by 30% in patients with relapsed or refractory multiple myeloma, according to a new study published online in the New England Journal of Medicine and presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, this week.
For the phase III ELOQUENT-2 trial, researchers randomly assigned 646 patients with relapsed or refractory multiple myeloma to receive lenalidomide plus dexamethasone with or without elotuzumab.
Results showed that after a median follow-up of 24.5 months, the 1-year progression-free survival rate was 68% in the elotuzumab group versus 57% in the control group. The 2-year progression-free survival rates were 41% and 27%, respectively. Researchers found that median progression-free survival was 19.4 months in the elotuzumab group compared with 14.9 months in the control group.
In regard to safety, the most common grade 3 or 4 adverse events in both groups were fatigue, lymphocytopenia, neutropenia, and pneumonia. In the elotuzumab group, 10% of patients experienced infusion-related reactions, of which the majority were grade 1 or 2.
Addition of elotuzumab significantly reduced risk of disease progression in relapsed or refractory multiple myeloma.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|